Sierra Oncology, Inc.

GSK will have to wait three months longer for the US Food and Drug Administration to make a ruling on its myelofibrosis candidate momelotinib, with the agency pushing back its decision date to 16 Sep

Swedish Orphan Biovitrum AB (Sobi) said on 10 May that it will pay $1.7bn to acquire CTI BioPharma Corp. , buying an immediate source of revenue growth in the form of CTI’s Vonjo (pacritinib), appro

GSK has added to its recent run of acquisitions and in-licensing deals with the £1.6bn ($2bn) buyout of Bellus Health , a company with a potential best-in-class chronic cough drug in its pipeline. I

Biogen/Ionis’s Tofersen For SOD1 ALS Away from its adventures in Alzheimer’s disease, Biogen Pharma is hopeful of an accelerated US approval for tofersen, which it licensed from Ionis Pharmaceutica